Case study of a diabetic dog with chronic membranous glomerulopathy treated with continuous intraperitoneal insulin infusion.
The purpose of this study was to determine the use of continuous intraperitoneal insulin infusion over an extended period (in maintaining metabolic control) and to evaluate the benefits of this treatment in reversing the kidney pathology of a chronic diabetic dog with membranous glomerulopathy. Hyperglycemia was eliminated, but reevaluations of the insulin infusion pattern were necessary. An initial kidney biopsy revealed fusion of the foot processes, thickening of the basement membrane, and subendothelial deposition. After 5 months of infusion, there was less fusion of the foot processes and a decrease in the subendothelial deposition. Urinary protein loss decreased from 17.3 g/day to 625 mg/day after 2 months of infusion. The dog gained weight, muscle wasting was reversed, and his stamina returned while on continuous insulin infusion. The reduction of a life-threatening urinary protein loss to a tolerable level and the improvement in the microscopic kidney lesions observed indicate that this treatment with insulin infusion may be beneficial in the management of long-term diabetic dogs, affected with advanced kidney lesions secondary to diabetes.
D000496:Alloxan; D000818:Animals; D002408:Catheters, Indwelling / Q000662:veterinary; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007668:Kidney / Q000648:ultrastructure; D008297:Male; D008854:Microscopy, Electron; D010537:Peritoneum
D007328:Insulin; D000496:Alloxan